期刊文献+

Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma

Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma
原文传递
导出
摘要 The incidence of prostate cancer is rising in the Asia-Pacific region as well as other countries. Androgen-ablation therapy is clinically useful in the androgen-dependent phenotype however, many patients progress to hormone refractory prostate cancer that is difficult to treat and needs newer interventions that are more effective. The objective of this study was to determine functionally-relevant biological networks, to appreciate the potential crosstalk between signaling members, and to identify biomarker signatures in prostate cancer. We used microarray analyses to identify key genes that were upregulated or down regulated at least five-fold in human prostate cancer and constructed canonical interaction networks that are important in prostate cancer through metabolomics analyses. Our prostate cancer network architecture revealed several key biomarkers including ERK1/2, JNK, p38, MEK, PI3 K, NFκB, AP-1, 14-3-3, VEGF, PDGF, Rb, WNT8 A, WNT10 A, CD44, ESR2, FSH and LH. Furthermore, the top ten transcription factors identified by TFBS-association signature analysis in the regulatory elements of co-regulated biomarkers were delineated, which may crosstalk with upstream or downstream genes elicited in our network architecture. Taken together, our results demonstrate that the regulatory interaction networks in prostate cancer provide a universal view of crosstalk between important biomarkers, i.e., key players in the pathogenesis of this disease. This will facilitate more rapid screening of functional biomarkers in early/intermediate drug discovery. The incidence of prostate cancer is rising in the Asia-Pacific region as well as other countries. Androgen-ablation therapy is clinically useful in the androgen-dependent phenotype however, many patients progress to hormone refractory prostate cancer that is difficult to treat and needs newer interventions that are more effective. The objective of this study was to determine functionally-relevant biological networks, to appreciate the potential crosstalk between signaling members, and to identify biomarker signatures in prostate cancer. We used microarray analyses to identify key genes that were upregulated or down regulated at least five-fold in human prostate cancer and constructed canonical interaction networks that are important in prostate cancer through metabolomics analyses. Our prostate cancer network architecture revealed several key biomarkers including ERK1/2, JNK, p38, MEK, PI3 K, NFκB, AP-1, 14-3-3, VEGF, PDGF, Rb, WNT8 A, WNT10 A, CD44, ESR2, FSH and LH. Furthermore, the top ten transcription factors identified by TFBS-association signature analysis in the regulatory elements of co-regulated biomarkers were delineated, which may crosstalk with upstream or downstream genes elicited in our network architecture. Taken together, our results demonstrate that the regulatory interaction networks in prostate cancer provide a universal view of crosstalk between important biomarkers, i.e., key players in the pathogenesis of this disease. This will facilitate more rapid screening of functional biomarkers in early/intermediate drug discovery.
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第1期12-27,共16页 中国药学(英文版)
基金 RO1 CA 094828 to Prof. Ah-Ng Tony Kong and in part by R21 CA133675 to Dr.Li Cai both from the National Institutes of Health(NIH)
关键词 Human prostate cancer MICROARRAY Biological network BIOMARKER 前列腺癌 微阵列 生物学网 生物标记
  • 相关文献

参考文献53

  • 1Baade, P.D.; Youlden, D.R.; Cramb, S.M.; Dunn, J.; Gardiner, R.A. Prostate Int. 2013, 1, 47-58.
  • 2Takiar, R.; Kumar, S. Asian Pac. J. Cancer Prev. 2014, 15, 599-603.
  • 3Centers for Disease Control and Prevention (CDC) Available at http://www.cdc.gov/cancer/prostate/basic_info/.
  • 4U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta (GA).
  • 5National Cancer Institute (NCI) Available at http://seer. cancer.gov/statfacts/html/prost.html.
  • 6Skolarus, T.A.; Wolin, K.Y.; Grubb, R.L.3rd. Nat. Clin. Pract. Urol. 2007, 4, 605-614.
  • 7Bostwick, D.G. Urology. 1989, 34, 16-22.
  • 8Hallstrom, T.M.; Laiho, M. Prostate. 2008, 68, 902-918.
  • 9De Marzo, A.M.; Putzi, M.J.; Nelson, W.G. Urology. 2001, 57, 103-114.
  • 10MacRae, E.J.; Giannoudis, A.; Ryan, R.; Brown, N.J.; Hamdy, F.C.; Maitland, N.; Lewis, C.E. Prostate. 2006, 66, 470-494.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部